Posted inResearch
Merck KGaA’s MilliporeSigma absorbs Dutch organoid maker HUB Organoids
Through its U.S. and Canada life science business MilliporeSigma, Merck KGaA is acquiring Dutch company HUB Organoids. The deal is…
Posted inBiotechnology
Ring Therapeutics lays off just under half of staff in 2nd wave of cuts this year, CEO set to step down
Ring Therapeutics, a Flagship Pioneering-backed biotech developing new viral vectors for gene therapy delivery, has cut its staff by just…
Posted inGenetics
Spatial Transcriptomic Clocks Reveal Local Cellular Interactions Influence Brain Aging
Certain cells in the brain create a nurturing environment, enhancing the health and resilience of their neighbors, while others promote…
Posted inBiotechnology
Novartis, BioAge take on age-related diseases in $550M pact
Freshly public BioAge Labs has secured a multi-year partnership with Novartis that focuses on age-related diseases and includes the possibility…
Posted inMedical Technology
Roche to bring mass spec to routine labs with new cobas system’s European approval
Roche has begun rolling out a new diagnostics system that aims to bring the gold-standard accuracy of mass spectrometry to…
Posted inBiotechnology
Fibrosis-focused Tvardi to go public via merger with cash-strapped Cara
Pruritus drug developer Cara Therapeutics kicked off the year halving its headcount, and the biotech has now found a new…
Posted inBiotechnology
Merck & Co. boosts GLP-1 portfolio by paying $112M upfront for Hansoh’s preclinical drug
Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for…
Posted inBiotechnology
Aurion’s regenerative eye disease med improves vision in phase 1/2 trial
The highest dose of Aurion Biotech’s cell therapy, the main component of which recently received approval in Japan, has improved…
Posted inBiotechnology
Cognition’s phase 2 SHIMMER results finally allow dementia drug to shine
The failure of Cognition Therapeutics’ Alzheimer’s disease candidate CT1812 in the SHINE trial earlier this year may have rubbed off…
Posted inGenetics
Nvidia’s Venture Arm Raises Stake in AI Drug Discoverer Genesis Therapeutics
Evan Feinberg, PhD, founder and CEO of Genesis Therapeutics In the beginning, Genesis Therapeutics spun out from the Stanford University…